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Abstract: Fosfomycin is a bactericidal, low-molecular weight, broad-spectrum antibiotic, with
putative activity against several bacteria, including multidrug-resistant Gram-negative bacteria,
by irreversibly inhibiting an early stage in cell wall synthesis. Evidence suggests that fosfomycin
has a synergistic effect when used in combination with other antimicrobial agents that act via
a different mechanism of action, thereby allowing for reduced dosages and lower toxicity. Fosfomycin
does not bind to plasma proteins and is cleared via the kidneys. Due to its extensive tissue
penetration, fosfomycin may be indicated for infections of the CNS, soft tissues, bone, lungs, and
abscesses. The oral bioavailability of fosfomycin tromethamine is <50%; therefore, oral administration
of fosfomycin tromethamine is approved only as a 3-gram one-time dose for treating urinary
tract infections. However, based on published PK parameters, PK/PD simulations have been
performed for several multiple-dose regimens, which might lead to the future use of fosfomycin for
treating complicated infections with multidrug-resistant bacteria. Because essential pharmacological
information and knowledge regarding mechanisms of resistance are currently limited and/or
controversial, further studies are urgently needed, and fosfomycin monotherapy should be avoided.
Keywords: fosfomycin; pharmacokinetics; multidrug resistance; antimicrobial activity
1. Introduction
The discovery of antibiotics in the 1920s was one of the greatest breakthroughs in the history of
healthcare, leading to a marked decrease in both morbidity and mortality associated with bacterial
infections [1]. However, the intensive and extensive use and misuse of antibiotics over the past
50 years has contributed to the emergence and spread of antibiotic-resistant bacterial strains [2–4]. This
increase and global spread of multidrug-resistant (MDR) bacteria is particularly alarming [3,5], and
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the World Health Organization has identified antibacterial drug resistance as a major threat to global
public health.
The decrease in the number of effective antibiotics—together with a relative paucity of new
antimicrobial drugs—is particularly relevant for treating infections with Gram-negative MDR
bacteria [6–8]. To overcome this problem, the reassessment and reintroduction of “old” antibiotics
has emerged as a viable strategy [9,10]. However, these antibiotics were never subjected to the
rigorous drug development program that is currently mandatory for receiving marketing authorization.
Thus, the pharmacological information needed in order to develop optimal dosing regimens with
maximal activity and minimal toxicity is limited [9,11]. One such “old” antibiotic is fosfomycin,
a broad-spectrum antibiotic that was originally developed more than 45 years ago. Because it has
both in vitro and in vivo activity against a wide range of MDR bacteria, as well as XDR (extensively
drug-resistant) and PDR (pan-drug-resistant) bacteria, fosfomycin is potentially a good candidate for
treating infections with these bacteria [12–18].
In this review, we discuss the potential for using fosfomycin to treat MDR bacterial infections.
Specifically, we review the currently available pharmacological data, with a focus on the chemistry,
pharmacokinetics, pharmacodynamics, and clinical use of fosfomycin.
2. Methods
2.1. Systematic Search Strategy
The PUBMED/MEDLINE and OVID/EMBASE databases were searched systematically in
February 2016 to identify all published relevant articles regarding fosfomycin. To be as comprehensive
as possible, the search terms included synonyms of fosfomycin in the article titles.
The search strategies were designed and performed by a specialist librarian and were restricted
to journals published in English or Dutch. No other publication or date restrictions were applied.
A comprehensive database of the retrieved articles was created, and duplicate publications were
removed. The abstract of each identified publication was then independently reviewed by the
first author (A.C. Dijkmans) and last author (I.M.C. Kamerling). We then obtained and reviewed
the full-text version of all articles that focused on multidrug-resistant Gram-negative bacteria (e.g.,
Enterobacteriaceae, A. baumannii, and P. aeruginosa), pharmacokinetics, pharmacodynamics, critically
ill patients, treatment outcome, and/or mode of action. To search for any additional relevant articles,
we screened the reference lists of the full-text articles, as well as relevant guidelines and references
from the cited product information.
A final check was performed prior to submission of the manuscript in order to update the
systematic search and include any new publications.
2.2. PUBMED/MEDLINE
PUBMED/MEDLINE was searched using the following terms: (“Fosfomycin”[Majr] OR
phosphomycin[ti] OR fosfomycin[ti] OR phosphonomycin[ti] OR fosfonomycin[ti] OR monuril[ti]
OR tromethamine[ti] OR trometamine[ti] OR trometamol[ti] OR tromethamol[ti]) AND (eng[la] OR
dut[la]).
2.3. OVID/EMBASE
OVID/EMBASE was searched using the following terms: (exp *fosfomycin/ OR phosphomycin.ti.
OR fosfomycin.ti. OR phosphonomycin.ti. OR fosfonomycin.ti. OR monuril.ti. OR tromethamine.ti.
OR trometamine.ti. OR trometamol.ti. OR tromethamol.ti.) AND (english.lg. OR dutch.lg.).
3. Results
In total, our combined search of the databases PUBMED/MEDLINE and OVID/EMBASE
retrieved 3422 records; after 2135 duplicates were removed, 1287 unique publications were screened
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(Figure 1). Of the remaining 1287 records that were screened by title and abstract, 975 were excluded
as they were judged not relevant to the topic. The remaining 312 records were examined as full-text
articles, and an additional 251 were excluded, leaving 61 articles. An additional 31 articles were
identified by manually checking the included publications and product information. Thus, a total of
92 articles were included in our analysis.
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Figure 1. Flow-chart depicting the systematic search process and articles included.
4. Pharmacology of Fosfomycin for Treating MDR Bacteria
4.1. Chemistry
Fosfomycin is a bactericidal broad-spectrum antibiotic first isolated in 1969 from cultures of
Streptomyces spp. [19]. Fosfomycin, which is currently produced using a synthetic process, is a
low-molecular weight (138 g/mol), highly polar phosphonic acid derivative (cis–1,2-epoxypropyl
phosphonic acid) that represents its own class of antibiotics [20]. Fosfomycin was initially marketed
as both a calcium salt formulation (fosfomycin calcium) for oral administration and a more
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hydrophilic disodium salt (fosfomycin disodium) for parenteral administration. Later, because of
its improved bioavailability, fosfomycin tromethamine became the standard formulation for oral
administration [20,21]. The chemical structures of the various formulations of fosfomycin are shown
in Figure 2.
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4.2. Pharmacokinetics of Fosfomycin
4.2.1. Absorption
Orally administered fosfomycin is absorbed partially in the small intestine via two proposed
mechanisms: (i) a saturable carrier-mediated system associated with a phosphate transport system,
and (ii) a non-saturable process with first-order kinetics [2 ]. Studies with fosfomycin calcium have
shown that before reaching the small intestine, fosfomycin undergoes acid-catalyzed hydrolysis in
the stomach, where intragastric acidity and gastric emptying rate can affect the extent of fosfomycin’s
hydr lyti degradati n and—conseque tly—its bioavailability [23]. Variations between individuals
with r spect to intr gastric acidity and gastric emptying r te may also ex lai the high variability in
serum levels achieved after oral administration of fosfomycin [23,24].
Tromethamine is a pH-elevating (i.e., alkaline) organic compound believed to slow acid-catalyzed
hydrolysis. As mentioned above, fosfomycin tromethamine is now the preferred oral formulati n
due to its improv d properties compa ed to fosfomycin calcium, includi g higher bioavailability (F)
which ranges from 33% to 44% [21,25,26] (compared to 12–37% for th calcium salt [21,27,28]). When
bioavailability was calculated from urinary excretion data following oral and IV administration of
fosfomycin tromethamine, values as high s 58% have been calculated [25]. Although the bioav ilability
of both salts is reduced when taken orally following food [24,29], when taken under fasting conditions,
serum conc ntrations f the trom thamine salt are approximately 2–4-fold higher than the calcium
formulation [21,30]. However, because no cross-over study has be n performed, a systematic study of
bioavailability is recommended.
Despite the improved bioavailability chieved with orally administered fosfomycin trometha ine,
maximum co centr tions (Cmax) of fosfomycin are still well below th Cmax values achiev d following
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IV administration [21,31]. For example, 2–2.5 h after a single fasting oral dose of fosfomycin
tromethamine at 3 g (approximately 50 mg/kg body weight), Cmax is 21.8–32.1 mg/L, with a total area
under the serum concentration-time curve (AUC) of 145–193 mg·h/L [21,25,26]. In contrast, after IV
administration of the same dose of fosfomycin disodium, Cmax was 276–370 mg/L, with an AUC of
405–448 mg·h/L [21,25,26].
4.2.2. Distribution and Tissue Penetration
Fosfomycin binds to plasma proteins at only negligible levels [31] and is distributed widely into
a variety of tissues; in addition to serum, biologically relevant concentrations of fosfomycin have been
measured in the kidneys, bladder, prostate, lungs, bone, and cerebrospinal fluid, as well as in inflamed
tissues and abscess fluid [32–40].
The apparent volume of distribution (Vd/F) following oral administration of fosfomycin
tromethamine is approximately 100–170 L for a 70-kg individual [29,30]. In contrast, because of
its higher bioavailability, IV-administered fosfomycin disodium has a reported Vd of 9–30 L at
steady state, and values of 3–12 L have been reported for both the central (Vc) and peripheral (Vp)
compartments [25,27,28,32,36,41,42].
4.2.3. Metabolism and Excretion
Approximately 90% of an IV dose of 3 g fosfomycin disodium is recovered unchanged in the urine
36–48 h after dosing [21,25,26]. In contrast, only 40–50% of a 3 g oral dose of fosfomycin disodium is
recovered; this difference compared to an IV dose is due primarily to incomplete absorption of oral
fosfomycin disodium [21,25,26,29]. Following an oral dose of fosfomycin tromethamine, approximately
10% of the original dose is recovered unchanged in the feces [29].
Segre et al. reported that the fraction of the original dose excreted in the urine decreases as the
oral dose increases [25], suggesting decreased absorption at higher doses. However, their study used
a relatively limited range of doses (2, 3, and 4 g) in a small number of individuals (n = 12). On the
other hand, urinary concentrations >128 mg/L are maintained 24–48 h after an oral dose of 2, 3, or 4 g
and 12–24 h after an IV dose of 3 g [26].
In general, the total clearance rate ranges from 5 to 10 L/h, whereas renal clearance ranges
from 6 to 8 L/h [25,27,31,32,35,36,41,43]. Fosfomycin has also been detected in the bile, with biliary
concentrations of approximately 20% of the serum concentration [31,44,45]. Given this finding, Segre
et al. suggested that fosfomycin undergoes biliary recirculation, based on the presence of secondary
peaks in serum drug concentration following oral administration and based on the concentrations of
fosfomycin measured in the bile [25,31,38,44,45].
In healthy individuals, IV fosfomycin is distributed in and eliminated from the serum in a
bi-exponential manner; the serum disposition half-life (t1/2α) of fosfomycin is 0.18–0.38 h [28,43], and
the terminal (or elimination) half-life (t1/2β) of fosfomycin is 1.9–3.9 h [21,25–28,32,35,36,43]. In contrast,
the t1/2β is longer following an oral dose of fosfomycin tromethamine (3.6–8.28 h [21,26,30]), which
can be explained by a longer absorption phase. In patients who have renal failure and/or are receiving
hemodialysis, the t1/2β of fosfomycin can be as long as 50 h, depending on the level of renal function;
therefore, the dosing schedule should be adjusted accordingly, particularly if creatinine clearance
(CLCR) drops below 40 mL/min [43,44,46].
An overview of the farmacokinetics is given in Table 1.
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Table 1. Overview of the reported pharmacokinetic properties of fosfomycin calcium, fosfomycin tromethamine, and fosfomycin disodium.
Ref Dose Study Group (N) Tmax (h) t1/2β (h) Vd (L) CL (L/h) CLR F (%) ka kel Q
Fosfomycin calcium
Cadorniga et
al., 1977 [28] 500 mg HV (6) 2–2.5 2.04 20.7 ND ND 37 ND 0.12 NA
Goto et al.,
1981 [27] 20 mg/kg HV (7) 2.3 (0.3) 3.01 (0.67)
g 30.1 (4.6) 7.1 (1.5) ND 28 (7.0) 1.03 (0.38) 0.24 (0.05) NA
40 mg/kg HV (7) 2.7 (0.2) 5.05 (0.81) g 60.2 (17.4) 9.0 (1.7) ND 28 (8.0) 0.92 (0.40) 0.14 (0.02) NA
Borsa et al.,
1988 [30] 40 mg/kg SD Young HV (5) 1.41 (0.67) 4.81 (1.90)
g 435.0 (144.0) 59.3 (23.3) a 5.0 (1.1) a ND ND 0.170 (0.084) NA
Elderly HV (8) 2.58 (0.54) 11.80 (6.86) g 409.4 (100.4) 33.4 (23.1) a 3.3 (1.1) a ND ND 0.082 (0.047) NA
Bergan et al.,
1990 [21] 50 mg/kg HV (8) 2.9 (0.6) 5.6 (1.8)
g ND ND ND 12.0 (7.5) ND 0.135 (0.053) NA
Fosfomycin tromethamine
Segre et al.,
1987 [25] 50 mg/kg HV (5) 2.2 (0.44) 2.43 (0.31) 10.4 (1.5) 8.3 (1.6) 7.0 (0.9)
0.44 (0.09)
0.58 (0.04) e
Transit model
k10: 1.24 (0.55)
k12: 1.69 (0.62)
k23: 0.34 (0.10)
k35: 0.69 (0.07)
f NA
Borsa et al.,
1988 [30] 25 mg/kg SD Young HV (5) 1.61 (0.23) 5.37 (2.56)
g 186.3 (129.4) 19.4 (8.4) a 10.8 (1.5) a ND ND 0.156 (0.073) NA
Elderly HV (8) 2.16 (0.72) 8.28 (5.51) g 101.1 (61.2) 9.7 (4.2) a 2.9 (1.0) a ND ND 0.124 (0.078) NA
Bergan et al.,
1990 [21] 25 mg/kg HV (8) 2.6 (0.5) 3.9 (0.65)
g ND ND ND ND ND 0.183 (0.031) NA
50 mg/kg HV (8) 2.5 (0.8) 3.6 (0.44) g ND ND ND 40.6 (17.9) ND 0.197 (0.024) NA
Bergan et al.,
1993 [26] 2 g HV (12) 2.2 (0.9) 4.1 (0.8)
g ND ND ND ND ND 0.17b NA
3 g HV (12) 2.0 (0.6) 4.5 (2.1) g ND ND ND 32.9 (7.9) ND 0.15b NA
4 g HV (12) 2.0 (0.0) 3.9 (0.7) g ND ND ND ND ND 0.18b NA
Fosfomycin disodium
Kwan et al.,
1971 [42]
250 or 500 mg, 10-min
infusion, Single dose
500 mg every 6 h,
8 times.
HV (17) NA 1.1 c Vc: 12.9 7.5 7.1 NA NA K13: 0.62
12.4 b
k12: 0.96
k21: 1.19
Cadorniga et
al., 1977 [28] 500 mg, 5-min infusion HV (6) NA
t1/2α: 0.38
t1/2β: 2.04
Vc: 12.9
Vp: 7.8
Vdss: 20.7
ND ND NA NA K13: 0.67
6.9 b
k12: 0.54
k21: 0.88
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Table 1. Cont.
Ref Dose Study Group (N) Tmax (h) t1/2β (h) Vd (L) CL (L/h) CLR F (%) ka kel Q
Goto et al.,
1981 [27]
20 mg/kg, 5-min
infusion HV (7) NA 2.25 (0.74)
Vc: 8.7 (2.9)
Vp: 9.8 (1.7)
Vdss: 18.5 (4.6)
7.2 (1.6) 6.0 (2.2) NA NA β: 0.34 (0.12)k10: 0.92 (0.31)
14.2 b
k12: 1.62 (0.76)
k21: 1.45 (0.75)
40 mg/kg, 5-min
infusion HV (7) NA 2.22 (0.46)
Vc: 8.7 (2.9)
Vp: 12.7 (2.9)
Vdss: 20.8 (3.5)
8.0 (0.8) 6.6 (0.9) NA NA β: 0.32 (0.06)k10: 0.99 (0.22)
16.2 b
k12: 1.84 (0.85)
k21: 1.30 (0.49)
Lastra et al.,
1983 [43] 30 mg/kg
Patients with
normal renal
function (9)
NA t1/2α: 0.18 (0.09)t1/2β:1.91 (0.50)
21.2 (10.4) 7.9 (3.2) ND NA NA k13: 1.91 (1.29)
k12: 2.22 (1.49)
k21: 1.18 (0.68)
Patients with
impaired renal
function (8)
NA t1/2α: 0.61 (0.18)t1/2β: 16.3 (11.9)
17.8 (6.8) 1.1 (0.8) ND NA NA k13: 0.21 (0.17)
k12: 0.66 (0.38)
k21: 0.43 (0.13)
Segre et al.,
1987 [25]
50 mg/kg, Single
injection HV (5) NA 2.43 (0.31) 10.4 (1.5) 8.3 (1.6) 7.0 (0.9) NA NA
k35: 0.69 (0.07)
f
10.6 b
k34: 1.00 (0.92)
k43: 1.40 (0.91)
Bergan et al.,
1990 [21]
50 mg/kg, 5-min
infusion HV (8) NA 3.4 (1.1) ND ND ND NA NA 0.206 (0.048) ND
Bergan et al.,
1993 [26] 3 g HV (12) 0.02 (0.0) 2.1 (0.1) ND ND ND NA NA 0.33
b ND
Joukhadar et
al., 2003 [35] 8 g, 20-min infusion
Critically ill
patients (9) 0.4 (0.1) 3.9 (0.9) 31.5 (4.5) 7.2 (1.3) ND NA NA 0.18
b ND
Pfausler et al.,
2004 [32]
8 g, 30-min infusion,
Single dose
Patients requiring
extraventricular
drainage (6)
1.2 (0.4) 3.0 (1.0) 30.8 (10.2) 7.4 (2.3) ND NA NA ND ND
8 g, 30-min infusion,
every 8 h for 5 days
Patients requiring
EVD 1.5 (1.2) 4.0 (0.5) 26.3 (9.7) 5.0 (2.0) ND NA NA ND ND
Sauermann et
al., 2005 [36]
8 g, 30-min infusion,
Single dose Patients (12) 0.47 (0.12) 3.7 (2.2)
Vc: 15.5 (4.5)
Vdss: 28.6 (9.9)
7.6 (4.1) ND NA NA 0.19 b ND
Kjellsson et al.,
2009 [41]
8 g, 30-min infusion,
Single dose Patients (12) NA 1.2
c
Vc: 10.1
(5.4–14.8)
Vp: 9.80
(5.7–13.9)
5.8 (3.8–7.8) ND NA NA 0.58 d 15.4 (9.1–21.6)
HV, healthy volunteers; N, number of subjects; Vd, apparent volume of distribution (unless specified as another reported volume); CLR, renal clearance; F, bioavailability; ka, apparent
first-order absorption rate constant; kel, apparent first-order elimination rate constant; Q, intercompartmental clearance. a Calculated in L/h per 1.73 m2, b Calculated from kel and k12, k21.
Q = k12*V1 and Q = k21*V2, c Calculated using the equation t1/2 = 0.693/kel, d Calculated from CL and central Vd the equations Kel = CL/Vc and Kel = 0.693/t1/2, e Bioavailability
calculated using the PK model (F = k12/(k12+k10)) and the ratio of the amount excreted in the urine after oral and IV administration, f Rate of elimination in the urine, g Apparent
terminal half-life.
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4.3. Pharmacodynamics of Fosfomycin
4.3.1. Mechanism of Action
In general, antibiotics exert their bactericidal or bacteriostatic activity by targeting the
microorganism’s essential physiological and/or metabolic functions, including protein, DNA, RNA,
or cell wall synthesis and cell membrane organization. Fosfomycin has a unique mechanism of action
in which it irreversibly inhibits an early stage of bacterial cell wall biosynthesis.
In order to exert its bactericidal activity, fosfomycin must reach the bacterial cytoplasm. To enter
the cell, fosfomycin uses the active transport proteins GlpT and UhpT by mimicking both glucose-6-P
(G6P) and glycerol-3-P (G3P). Thus, fosfomycin can be imported into the bacterial cell via the hexose
monophosphate transport system (which is induced by G6P) and via the L-a-glycerophosphate
transport system (which is induced by G3P) [20,47]. Once in the cytoplasm, fosfomycin acts as
an analog of phosphoenolpyruvate (PEP) and binds MurA (UDP-GlcNAc enopyruvyl transferase),
thereby inactivating the enzyme enolpyruvyl transferase, an essential enzyme in peptidoglycan
biosynthesis [48]. Thus, fosfomycin prevents the formation of UDP-GlcNac-3-O-enolpyruvate from
UDP-GlcNAc and PEP during the first step in peptidoglycan biosynthesis, thereby leading to
bacterial cell lysis and death (Figure 3) [47]. In addition, fosfomycin also decreases penicillin-binding
proteins [49].
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4.3.2. Antibacterial Activity
Because both Gram-negative and Gram-positive bacteria require N-acetylmuramic acid for cell
wall synthesis, fosfomycin is as a broad-spectrum antibiotic with activity against a wide range of
bacteria, including Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter spp., Citrobacter
spp., and Salmonella typhi [12,20,50–52]. However, due to a paucity of preclinical and clinical data,
no universally accepted minimum inhibitory concentration (MIC) values have been defined for the
susceptibility and resistance to fosfomycin; overall, the MIC for susceptibility ranges from ≤32 to
≤64 mg/L, and the MIC for resistance ranges from >32 to >256 mg/L, according to the Clinical and
Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) [14,53].
Several studies have investigated the microbiological activity and efficacy of fosfomycin against
several MDR, XDR, and PDR strains of Gram-negative bacteria. In this respect, fosfomycin has
been reported to have both in vitro and in vivo activity against several MDR and XDR species
of Enterobacteriaceae, including species that express extended-spectrum β-lactamases (ESBL) and
metallo-β-lactamases (MBL) [14–18]. Due to the broad range of MIC values and differences in methods
used to test susceptibility (e.g., agar dilution, microdilution, E-test), it is difficult to compare the results
of different studies. However, given that some studies found that more than 90% of MDR and XDR
isolates are susceptible to fosfomycin, fosfomycin is a promising candidate for treating infections with
these pathogens [15,16], provided that in vivo results support the in vitro data.
MDR P. aeruginosa and A. baumannii are Gram-negative pathogens primarily responsible for
nosocomial (i.e., hospital-acquired) infections, particularly in intensive care units [54]. A systematic
review of microbiological, animal, and clinical studies using non-fermenting Gram-negative bacilli
concluded that using fosfomycin in combined therapy may provide a safe and effective therapeutic
option for treating infections due to MDR P. aeruginosa [13]. The clinical efficacy of fosfomycin against
MDR-bacteria, including P. aeruginosa, has been suggested in patients with severe infections and critical
conditions [18], and in cystic fibrosis patients with infective pulmonary exacerbations [55,56]. However,
when used as monotherapy, P. aeruginosa should generally be regarded resistant to fosfomycin [57]
and its use in P. aeruginosa infections should ideally be reversed for additional evaluation in clinical
studies because the increased bacterial killing of combination therapy does not prevent the emergence
of fosfomycin resistance [58]. In contrast, nearly all isolates of A. baumannii are resistant to fosfomycin,
with a MIC90 value higher than 512 mg/L and there are no data on its use in combination therapy [14].
5. Fosfomycin Resistance
Three separate mechanisms of fosfomycin resistance have been reported [59]. The first mechanism
is based on decreased uptake by the bacterium due to mutations in the genes that encode the
glycerol-3-phosphate transporter or the glucose-6-phosphate transporter [47,60,61]. The second
mechanism is based on point mutations in the binding site of the targeted enzyme (MurA) [62],
and several isolates of E. coli have clinical resistance levels (32 mg/L) due to increased expression of
the murA gene [63].The third mechanism of resistance is based on the inactivation of fosfomycin
either by enzymatic cleavage of the epoxide ring or by phosphorylation of the phosphonate
group. In the presence of the metalloenzymes FosA, FosB, and FosX, the epoxide structure is
cleaved, with glutathione (FosA), bacillithiol and other thiols (FosB), or water (FosX) serving as
the nucleophile [64]. With respect to the phosphorylation of the phosphonate group, FomA and FomB
are kinases that catalyze the phosphorylation of fosfomycin to the diphosphate and triphosphate states,
respectively [65,66]. Fosfomycin dosing regimens that include a total daily dose of up to 24 g per day
resulted in the emergence of a resistant subpopulation within 30–40 h of drug exposure, suggesting
that resistance can occur rapidly.
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5.1. In Vitro Synergy between Fosfomycin and Other Antibiotics
The use of combined antimicrobial therapy is recommended in specific patient populations and
indications, including critically ill patients who are at high risk for developing an MDR bacterial
infection and patients with a P. aeruginosa infection [11,67,68]. In this regard, fosfomycin has an in vitro
synergistic effect of up to 100% when combined with other antimicrobial agents [69].
The synergistic effect between fosfomycin and β-lactam antibiotics is proposed to arise from the
inhibition of cell wall synthesis at separate steps; fosfomycin inhibits the first enzymatic step, whereas
β-lactam antibiotics inhibit the final stage in the cell wall synthesis process [70]. In addition, fosfomycin
may modify the activity of penicillin-binding proteins, which may account for the synergistic effect
between fosfomycin and β-lactam antibiotics [49,71,72]. Another study found that the synergistic
effect between fosfomycin and ciprofloxacin is due to ciprofloxacin-mediated damage to the outer
membrane, which increases the penetration and activity of fosfomycin [73]. With respect to P. aeruginosa,
several in vitro studies found synergy between fosfomycin and a variety of other antibiotics, including
aztreonam, cefepime, meropenem, imipenem, ceftazidime, gentamycin, amikacin, ciprofloxacin, and
others [70,74,75]. In addition, a few studies measured the synergistic effect of combining fosfomycin
with amikacin or sulbactam against A. baumannii strains, providing evidence that these drugs might
provide an effective combination therapy for infections with this pathogen [76,77]. Fosfomycin also
has synergistic effects when combined with other antibiotics for treating methicillin-resistant S. aureus,
Streptococcus, Enterococcus, and Enterobacteriaceae species [69,70]. In addition to increasing antibacterial
efficacy, fosfomycin can also reduce toxicity associated with other antibiotics such as aminoglycosides,
glycopeptides, and polymyxin B, as lower doses of these drugs can be prescribed [78–80].
5.2. Properties of Fosfomycin
The reintroduction of “old” antimicrobial agents to treat MDR bacteria requires optimization of
the dosing regimen. This optimization includes obtaining a thorough understanding of the drug’s
pharmacokinetic (PK) and pharmacodynamic (PD) properties, thereby providing maximal antibacterial
activity while minimizing toxicity and the development of resistance [11]. However, some “old”
antibiotics, including fosfomycin, are currently used clinically despite uncertainty regarding the
required and/or optimal exposure [11]. Therefore, it is essential to determine a rational dosing regimen
based on the drug’s PK/PD properties when introduced as a therapy against MDR bacteria.
5.3. PK/PD Properties
Because the exposure-response relationship can differ between antibiotics, it is important to define
the correct PK/PD index for each antibiotic in order to establish the PK/PD target value that will
maximize clinical efficacy [11,81,82]. With respect to antimicrobials, three PK/PD indices are commonly
used: T>MIC, which is the duration of time in which the drug concentration remains above the MIC
during a dose interval; Cmax/MIC, which is the drug’s Cmax divided by the MIC; and AUC/MIC,
which is the AUC measured over a 24-h period divided by the MIC.
Relatively few in vitro studies have been performed to characterize fosfomycin’s PK/PD
properties. Some such studies suggest that fosfomycin has a time-dependent bactericidal activity,
specifically against the Gram-positive S. aureus and S. pyogenes strains [32,35]; therefore, based
on these results T>MIC should be optimized. However, in vitro studies by Mazzei et al. [83] and
VanScoy et al. [84] suggest that fosfomycin shows a tendency towards a concentration-dependent
bactericidal activity against E.coli and P. mirabilis strain, achieving complete sterilization at
concentrations ≥4X MIC and ≥8X MIC, respectively. Moreover, an in vitro concentration-dependent
post-antibiotic effect (PAE) was observed for both E.coli and P. mirabilis 3.2–3.4 h at 0.25X MIC and
3.5–4.7 h at 8X MIC [83]. However, with respect to these studies, it is not clear whether the bactericidal
activity is concentration-dependent and/or time-dependent [85]. These studies however, do not
provide conclusive data on the concentration- or time depending nature of bactericidal activity.
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Therefore, the target PK/PD to achieve during therapy remains unknown, which is a major hurdle
that must be overcome in order to optimize therapy.
5.4. Current Clinical Indications for Fosfomycin and Potential Future Applications
5.4.1. Intravenous Administration
Fosfomycin disodium is currently available in only a few European countries—namely, Spain,
France, Germany, the United Kingdom, the Netherlands, Austria, and Greece—where it is approved
for the treatment of soft-tissue infection and sepsis. A Fosfomycin disodium adult dose of 12–24 g
daily is commonly administered in 2–4 separate infusions [51].
Due to is extensive tissue penetration, fosfomycin has emerged as a potential therapy for treating
infections in the central nervous system (CNS) [32], soft tissues [33,39,40], bone [39], lungs [34], and
abscesses [36]. Fosfomycin has high penetration into the interstitial fluid of soft tissues [40], reaching
50–70% of the levels measured in plasma, reaching sufficiently high levels to eliminate relevant
pathogens [33,40]. Moreover, Schintler et al. reported that fosfomycin might also be effective in treating
“deep” infections involving the osseous matrix [39].
With respect to CNS infections, Pfausler et al. reported that three daily IV doses of 8 g provided
a steady-state concentration of 16 mg/L in the cerebrospinal fluid (CSF) for more than 90% of the
interval between doses [32]. Moreover, the concentration of fosfomycin in the CSF can increase by
nearly threefold with meningeal inflammation [86]. With respect to suppurative lesions, Sauermann et
al. reported that repeated doses of IV fosfomycin can yield a concentration of 32 mg/L fosfomycin
in the abscess, albeit with high inter-individual variability in the PK of fosfomycin in the abscess
fluid [36,41].
MDR bacteria such as ESBL-producing bacteria and carbapenem-resistant bacteria are still
susceptible to fosfomycin [17,18], and fosfomycin is used in combination therapy for treating
these infections.
The repurposing of fosfomycin based on its activity against MDR Enterobacteriaceae is an
important strategy for addressing the ever-present threat of antimicrobial resistance. The AUC/MIC
seems to be the dynamically linked index for determining resistance suppression. In this respect, it
is essential to develop optimal dosing strategies for each MDR Enterobacteriaceae species based on
PK/PD data; moreover, additional dosing regimens may need to be developed for targeting different
tissue sites of infection in order to prevent the development of resistance. Another promising approach
is the use of combination therapy; for example, combining fosfomycin and meropenem yielded a
significant synergistic effect, but also yielded a significantly additive effect in the fosfomycin-resistant
subpopulation [87].
Currently, the FOREST study group is comparing the efficacy of combining fosfomycin with
meropenem in treating urinary tract infections (UTIs) with ESBL-producing E. coli [88].
5.4.2. Oral Administration
Fosfomycin tromethamine is currently approved for use in several European countries and is
only approved as a single 3-g dose for treating uncomplicated UTIs in women, specifically UTIs due to
E. coli infection [29]. Fosfomycin tromethamine has also been investigated as a potential therapy for
surgical prophylaxis in order to prevent prostate infection and even as a treatment for prostatitis due to
MDR Gram-negative bacteria [37]. The use of a multiple-dose regimen with fosfomycin tromethamine
has emerged as a potential strategy for treating of complicated and/or recurrent UTI, as well as
infections due to MDR bacteria [89–91]. In this respect, simulations of the urinary concentrations of
fosfomycin have been developed in order to determine the optimum dosing regimen that can provide
a urinary concentration above the MIC (i.e., >16 mg/L) for seven days [89]; these simulations suggest
that a single dose of 3 g administered every 72 h is sufficient to achieve the appropriate concentration.
In addition, an uncontrolled, open-label, multicenter study conducted in China found that a regimen
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of single 3-g doses of fosfomycin tromethamine administered at two-day intervals might provide
a safe, effective, and well-tolerated option for treating recurrent and/or complicated lower UTIs [90].
Thus, although the currently approved 3-g single dose of fosfomycin tromethamine is sufficient to
reach efficacious concentrations in the urine, it might not be sufficient to achieve serum and/or
tissue concentrations that are relevant for a clinical cure. A multiple-dose regimen of fosfomycin
tromethamine might therefore be warranted for the oral treatment of more severe infections.
Ortiz et al. conducted simulations of several multiple-dose regimens using a wide range of daily
doses of fosfomycin tromethamine and fosfomycin disodium [92]. The authors calculated PK/PD
indices, including Cmax/MIC, AUC/MIC, and %T>MIC, for each dosing regimen using a MIC of
8 mg/L. They concluded that a total daily dose of 6–12 g for microorganisms with a MIC of 8 mg/L
well exceeds the currently approved single dose of 3 g. However, the safety and tolerability of
fosfomycin tromethamine at such high doses has not been investigated. Nevertheless, further studies
are urgently needed in order to assess the PK, safety, tolerability, and efficacy of fosfomycin in both
multiple-dose regimens and synergistic combinations.
6. Conclusions
The World Health Organization currently recognizes that antibacterial drug resistance is one
of the major threats facing global public health, particularly given the reduction in the number of
effective antibiotics. In this respect, reassessing and reevaluating “old” antibiotics such as fosfomycin
has been proposed as a possible strategy in treating drug-resistant bacterial infections. Fosfomycin is
a broad-spectrum antibiotic with both in vivo and in vitro activity against a wide range of bacteria,
including MDR, XDR, and PDR bacteria. Thanks to its high tissue penetration, fosfomycin may be
used in a broad range of tissues and targets, including the CNS, soft tissue, bone, lungs, and abscess
fluid. Oral fosfomycin in a multiple-dose regimen has emerged as a potential strategy for treating
complicated UTIs and prostatitis; however, given the relative lack of essential information regarding
the pharmacological properties and mechanisms of resistance, additional studies are urgently needed.
In the meantime, using fosfomycin as a monotherapy should be avoided due to the rapid development
of resistance in vitro.
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